When does the semaglutide patent expire?

Novo Nordisk's core composition-of-matter patent for semaglutide (US Patent 8,129,343) expires in December 2031. Additional formulation patents protect Wegovy through late 2032 and Ozempic through early 2034. However, the foundational molecular exclusivity ends in 2031.

Who is developing semaglutide biosimilars?

At least nine companies have disclosed semaglutide biosimilar programs: Biocon Biologics, Teva Pharmaceutical, Samsung Bioepis, Sandoz, Dr. Reddy's, Celltrion, Fresenius Kabi, Viatris, and Gan & Lee Pharmaceuticals. Biocon has the most advanced publicly disclosed program with an ANDA filing in Q4 2025.

How much will biosimilar semaglutide cost?

Biosimilar semaglutide is expected to launch at 60-70% of branded pricing, roughly $400-600 per month compared to $1,000+ for branded Wegovy or Ozempic. This is based on pricing patterns from previous major biosimilar launches like adalimumab (Humira).

Will semaglutide biosimilars kill compounding pharmacies?

Biosimilar competition will compress the compounding industry's advantage. Currently, compounded semaglutide costs $200-400/month versus $1,000+ branded. When biosimilars launch at $400-600, the price gap narrows significantly. Major 503B facilities are already diversifying into non-GLP-1 peptides in anticipation.

How long does it take to develop a peptide biosimilar?

Peptide biosimilar development typically takes 5-7 years from program initiation to FDA approval. The process requires analytical characterization, animal pharmacokinetic studies, at least one clinical PK/PD bridging study, and potentially a large efficacy trial. Total cost is estimated at $200-400 million per program.

What is Novo Nordisk doing to protect against biosimilar competition?

Novo Nordisk has built a patent thicket of 40+ patents around semaglutide formulations, devices, and manufacturing processes to delay biosimilar entry. The company is also accelerating next-generation drugs like amycretin and CagriSema to migrate patients to newer, patent-protected compounds before the cliff.

PeptideKey News

Semaglutide Patent Cliff 2032: The $80B Biosimilar Race

Semaglutide core patents expire 2031-2032. Nine companies chase the largest biosimilar prize in pharma history. What it means for compounders and patients.

This article is part of PeptideKey's evidence-based peptide research library covering 100+ compounds with lab-verified purity data.